Detection of Oxidized LDL in Plasma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
1R43HL096442-01A1
Award Id:
93969
Agency Tracking Number:
HL096442
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
CARDIOVASCULAR SPECIALTY LABORATORIES, INC., 3781 PRESIDENTIAL PKWY, STE 11, ATLANTA, GA, 30340
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
065070760
Principal Investigator:
KENNETH DOMBROWSKI
(404) 327-4981
KEN.DOMBROWSKI@MED.VA.GOV
Business Contact:
NGOC LEE
() -
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): With 60% of plasma cholesterol being associated with low-density lipoproteins (LDL), reduction in LDLc is one of the primary targets for intervention to reduce cardiovascular disease. However, meta- analyses of availabl e clinical trials have consistently demonstrated that, while the risk for clinical event is reduced with LDLc reduction, the progression of atherosclerosis is not stopped. Many patients continue to have clinical events, including death, in spite of having reached target levels for LDLc. According to the oxidation hypothesis of atherosclerosis, native LDL is not atherogenic. LDL particles that have been oxidatively modified, on the other hand, can be avidly taken up by macrophages leading to the formation of foam cells and plaque instability. We have developed a number of specific and highly sensitive monoclonal antibodies against cysteic acid (oxidized form cysteine), which is one of the most common forms of naturally occurring protein oxidation. Preliminary data using the K2F1.6 clone (deposited with the ATCC PTA-897, US patent 6,953,666B1) indicates that a wide range of positive signals can be detected in high-risk individuals as compared to healthy controls. The objective of this SBIR Phase 1 is to demonst rate the clinical significance of this oxidative marker in a large cohort of patients with and without cardiovascular disease, including documented coronary artery disease. Specimen from three cohorts of patients will be available (1) free-living individua ls with and without CAD as characterized from medical history and endothelial dysfunction (brachial artery flow-mediated dilatation), (2) participants in the NIH funded Veterans Twin Heart Study characterized clinically by MRI and endothelial dysfunction, (3) veterans with type 2 diabetes mellitus with and without concomitant CAD who have been treated to LDLc goal. This will be a prospective, nested case-control single-blind study design. PUBLIC HEALTH RELEVANCE: Elevated plasma levels of oxidized LDL may c ontribute to the risk for future cardiovascular events beyond the traditional risk factors. Using a patent-protected ELISA assay based on a unique monoclonal antibody that recognizes an oxidized cysteine moiety, we propose to define the distribution of thi s oxidized epitope in three independent cohorts of subjects including healthy controls, patients with type 2 diabetes mellitus and patients with documented CAD.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government